MAGIC Composite Response for aGVHD
The MAGIC Composite Response (MCR) for aGVHD provides improved prediction of non-relapse mortality (NRM) after
approximately 28 days of aGVHD treatment. The MCR may be ordered after the treatment of aGVHD in bone marrow, stem cell, or other kinds of hematopoietic cell transplant recipients. This method combines the aGVHD Symptomatic Onset Algorithm, which is based on ST2 and Regenerating islet-derived 3-alpha (REG3α) levels, with a clinical assessment provided by the patient’s health care team. The clinical assessment is based on severity of skin, liver, upper GI and lower GI symptoms and yields a Manhattan risk score which is then combined with the MAGIC algorithm result to yield the MCR score. The MCR more accurately predicts 6-month NRM compared to clinical response or the MAGIC algorithm alone, demonstrating both higher positive and negative predictive value. The MCR accurately assesses long-term outcomes of both clinical responders and non-responders. For more information see: Akahoshi Y, et al. Blood Advances 2025 9(22):5763-5773, PMID: 40815797.
About the Test
The intended use of the MAGIC composite response is at approximately 28 days after initiating treatment for symptomatic aGVHD. The Manhattan risk score is based only on the clinical information derived from assessment of the clinical severity for skin, liver, upper GI, and lower GI systems. The Manhattan risk score yields four values (0, 1, 2 or 3) with 0 being the most favorable for patient outcomes. The MAGIC composite response score combines the Manhattan risk score and the aGVHD Symptomatic Onset Algorithm results to yield a score of 0, 1, 2 or 3 with 0 being most favorable. The MAGIC composite response improves prediction of 6-month NRM compared to either individual measure which may guide clinical decisions.
Same day (within 24 hours of receipt of specimen)
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| Serum | 403724P | 83006 ST2 and 83520 Reg3 | Yes | 0.5 mL (min. 0.5mL) |
|
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Eurofins Viracor test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor, 18000 W 99th St., Ste, #10, Lenexa, KS 66219.
Causes for RejectionSample maintained outside of validated stability conditions
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Eurofins Viracor’s interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References
Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant. 1990 Feb;5(2):69-82.
Ball LM, Egeler RM, EBMT Paediatric Working Party. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S58-64.
Choi B, Suh Y, Kim W-H, et al. Downregulation of regenerating islet-derived 3 alpha (REG3A) in primary human gastric adenocarcinomas. Exp Mol Med. 2007 39(6):796-804.
Closa D, Motoo Y, lovanna JL. Pancreatitis-associated protein: From a lectin to an anti-inflammatory cytokine. World J Gastroenterol. 2007 13(2):170-174.
Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant. 1990 Jul;6(1):1-8.
Gironella M, lovanna JL, Sans M, et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005 54:1244-1253.
Hartwell MJ, Ozbek U, Holler E, et al. An early-biomarker algorithm predicts lethal graft-versus-host-disease and survival. JCI Insight. 2017;2(3):e89798.
Harris AC, Ferrara JLM, Levine JE. Advances in predicting acute GVHD. British J Haematol 2013, 160:288-302.
Harris AC, Levine JE, Ferrara JL. Have we made progress in the treatment of GvHD? Best Pract Res Clin Haematol. 2012 Dec;25(4):473-8.
Harris AC, Ferrara JLM, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 119:2960-2963.
Jagasia M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012, 119(1):296–307.
Major-Monfried H, Renteria AS, Pawarode A., et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood 2018, 131(25):2846-2855.
Paczesny S, Krijanovski OI, Bruan TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 8;113(2):273-8.
Vander Lugt MT, Braun TM, Ferrara JLM, et al. Plasma Concentration of ST2, the IL33 Receptor, AIInitiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment. Blood. 2011 118(21).
Vander Lugt MT, Braun TM, Ferrara JLM, et al. Plasma Concentration of Suppressor of Tumorigenicity 2 (ST2), the IL33 Receptor, at lnitiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment. Biol Blood Marrow Transpl. 2012 February; 18 (2):S201-S202.
Margaret L. MacMillan, Marie Robin, Andrew C. Harris et al. A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality. Biol Blood Marrow Transplant. 2015 April ; 21(4): 761–767. doi:10.1016/j.bbmt.2015.01.001.
Yu Akahoshi,MD,PhD, Nikolaos Spyrou,MD, Daniela Weber,MD, et al. The Mount Sina iAcute Gvhd International Consortium (MAGIC) Model :An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease(GVHD). Abstracts/Transplantation and Cellular Therapy 302S(2024)S48-S53.